The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder

Dijkstra, Francis M; Loo, Aurora Jae van de; Abdulahad, Smedra; Bosma, Else; Hartog, Mitch; Huls, Hendrikje; Kuijper, Dianne C; Vries, Esther de; Solanki, Bhavna; Singh, Jaskaran; Aluisio, Leah; Zannikos, Peter; Stuurman, Frederik E.; Jacobs, Gabriël; Verster, Joris C.

doi:10.1177/02698811221078764

Cited by 6 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of psychotic features in MDD was not apparently associated with a different progression compared with non-psychotic depression during esketamine treatment (30). The impact of esketamine on cognitive functioning may be positive or neutral (37)(38)(39).…”

Section: Discussionmentioning

confidence: 99%

“…availability (44,45). Unlike the aforementioned reviews, in the present paper, studies regarding the cognitive effects of esketamine were included in healthy individuals and patients with MDD (37)(38)(39). Also, studies comparing ketamine and esketamine were included, as well as trials exploring both nasal spray and i.v.…”

Section: Advantages Disadvantagesmentioning

confidence: 99%

“…A single-blind, randomized, cross-titration study compared the effects of 84 mg intranasal esketamine vs. placebo on driving performance at 18±2 h post-administration ( 38 ). Another phase of the same study evaluated the impact of the same drug on driving ability at 6.0±0.5 h post-administration, in a regimen of esketamine delivered twice/week for three weeks ( 39 ). All patients had a diagnosis of mild-to-moderate MDD without psychotic features (n=27) ( 39 ).…”

Section: Efficacy Of Esketamine On Cognitive Functioningmentioning

confidence: 99%

“…Another phase of the same study evaluated the impact of the same drug on driving ability at 6.0±0.5 h post-administration, in a regimen of esketamine delivered twice/week for three weeks ( 39 ). All patients had a diagnosis of mild-to-moderate MDD without psychotic features (n=27) ( 39 ). In both the first and second phase, esketamine did not significantly alter driving performance compared with placebo ( 39 ).…”

Section: Efficacy Of Esketamine On Cognitive Functioningmentioning

confidence: 99%

See 3 more Smart Citations

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)

Vasiliu¹

2023

Exp Ther Med

View full text Add to dashboard Cite

Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the efficacy and safety of esketamine in the main categories of depressive disorders has been conducted through four electronic databases (Pubmed, Cochrane, EMBASE and Clarivate/Web of Science) The primary objective of the present review was to find evidence that may support the usefulness of esketamine for patients diagnosed with TRD as well as data about its potential adverse effects in the short and long term. A total of 14 papers were reviewed, and their results support the recommendation of esketamine for treatment of TRD as an add-on to antidepressants, but more data is needed in order to assess its long-term efficacy and safety. It must also be mentioned that there have been a few trials which did not report a significant effect on the severity of depressive symptoms with esketamine in TRD, therefore, caution is indicated for patients initiated on this adjuvant agent. There has been insufficient data to formulate specific guidelines about esketamine administration because evidence about favorable or negative prognostic factors of this treatment has been lacking, and the duration of its administration has not been unanimously accepted. Novel directions for research have been identified, especially in the case of patients with TRD and substance use disorders, geriatric or bipolar depression or in major depression with psychotic features. Contents1. Introduction 2. Objectives 3. Subjects and methods 4. Results overview 5. Short-term efficacy results 6. Efficacy of esketamine in lowering suicide risk 7. Efficacy of esketamine on cognitive functioning 8. Efficacy of esketamine in the prevention of depressive recurrence 9. Long-term results of esketamine administration 10. Safety profile of esketamine in clinical trials 11. Synthetic parameters 12. Limitations of the review 13. Conclusions

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Advantages Disadvantagesmentioning

confidence: 99%

Section: Efficacy Of Esketamine On Cognitive Functioningmentioning

confidence: 99%

Section: Efficacy Of Esketamine On Cognitive Functioningmentioning

confidence: 99%

See 2 more Smart Citations

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)

Vasiliu¹

2023

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance. To evaluate this, the effects of 84 mg intranasal esketamine on driving performance in unipolar major depressive disorder (MDD) or persistent depressive disorder (PDD) patients (Dijkstra et al, 2022) were examined. Interestingly, esketamine did not impair on-road driving performance the next morning following a single dose, or even on same day after repeated administration.…”

mentioning

confidence: 99%